|
|
 |
|
Viewing report
|
|
|
|
Insomnia - Drug Pipeline Analysis and Market Forecasts to 2015
GlobalData, Dec 2009, Pages: 46
Insomnia - Drug Pipeline Analysis and Market Forecasts to 2015
Summary
GlobalData, the industry analysis specialist’s new report, “Insomnia - Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global insomnia market. The report identifies the key trends shaping and driving the global insomnia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global insomnia sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Our team of industry experts.
Scope
The scope of the report includes
- Annualized global insomnia market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include GABA receptor targetters, serotonin receptor targetters, melatonin receptor agonists, histamine receptor antagonists, orexin receptor antagonists.
- Analysis of the current and future market competition in the global insomnia market. Key market players covered are Sanofi Aventis, Somaxon Pharmaceuticals, Vanda Pharmaceuticals Inc., Merck and GlaxoSmithKline.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with insomnia.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global insomnia market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global insomnia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global insomnia market landscape? - Identify, understand and capitalize.
Customers who bought this item also bought
Pipeline and Commercial Insight: Insomnia - Future of Innovative Orexin Drug Class in Doubt
The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Insomnia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012
The Central Nervous Systems Market 2010 Report
The Neurotechnology Industry 2011 Report
Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions
Sleeping Pills - Global Strategic Business Report
Pharmaceutical Partnership Deal Terminations
Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market
|
|
|
|
